Official Title
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
Brief Summary

This research study will evaluate the association of Androgen Receptor (AR) gene expression and COVID-19 disease severity and mortality. The research procedure involves collection of a single saliva sample which will be mailed to the participants by the study team. This saliva will be used in a COVID-19 Androgen Sensitivity Test (CoVAST) which will detect AR gene expression. Eligible participants are males, at least 18 years or older, and have tested positive for COVID-19.

Enrolling by invitation
COVID19
Androgen Receptor Gene Overexpression

Genetic: COVID-19 Androgen Sensitivity Test (CoVAST)
The CoVAST Test is an in-vitro non diagnostic test. The test reports the genetic health risk of male patients in developing severe symptoms following COVID 19 infection. The genetic information provided by this test will help physicians evaluate the association of AR gene polymorphism with disease severity and mortality following COVID-19 infection. The CoVAST Test is indicated for reporting of the following variant associated with the following gene.
Arm 1
Arm 2

Eligibility Criteria

Inclusion Criteria:

- Male over the age of 18

- Laboratory confirmed SARS-CoV-2 infection

- Able to give verbal informed consent

Exclusion Criteria:

- Unable to give informed consent

- Diagnosed with an additional respiratory co-infection

- XXY males

Eligibility Gender
Male
Eligibility Age
Minimum: 18 Years~Maximum: 90 Years
Countries
United States
Locations

Applied Biology, Inc
Irvine, California, 92614

University of California, Irvine - Dermatology Clinical Research
Irvine, California, 92697

Natasha Mesinkovska, MD, PhD
Principal Investigator
University of California, Irvine

University of California, Irvine
Applied Biology, Inc.
NCT Number
Keywords
androgen receptor
Severity
Mortality
MeSH Terms
Androgens